Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.

•Gemigliptin is an antihyperglycemic agent (AHA) proven to lower blood glucose potently and safely for patients with type 2 diabetes mellitus (T2D).•AHAs for post-transplant patients with T2D should have potent glycemic efficacy and general safety as well as no interactions with immunosuppressants.•Changes in blood glucose and safety parameters including renal function, liver enzymes, and blood level and dosage of immunosuppressants during 6 months of treatment of gemigliptin were assessed in this study.•Gemigliptin lowers blood glucose effectively and safely, without any significant influence on immunosuppressive treatment, in post-transplant patients with T2D.